Abstract
Dose-limiting toxicity to healthy tissues is among the major hurdles in anticancer treatment along with intrinsic or acquired multi-drug resistance. Development of small molecule inhibitors (SMI) specific for antiapoptotic Bcl-2 proteins is a novel approach in a way that these antagonists are aimed to interfere with specific protein-protein interactions unlike conventional chemo-/radiotherapies. SMIs of antiapoptotic Bcl-2 proteins are assumed to compete with proapoptotic Bcl-2s to occupy BH3 docking grooves on the surfaces of antiapoptotic family members. Instead of directly initiating cell death, these inhibitors are intended to decrease apoptotic threshold in tumor cells that were already primed to death. In this regard, antiapoptotic Bcl-2 protein SMIs have the advantage of lower normal tissue toxicity relative to conventional anticancer therapies that interfere with general mechanisms including DNA synthesis, mitosis and tyrosine kinase activity. Besides, Bcl-2 antagonists were shown to potentiate efficacies of established drugs in several hematological malignancies and solid tumors which render them promising candidates for combination anticancer therapy. Utilizing these SMIs in such a way may prove to decrease the patient drug load by diminishing the required chemo-/radiotherapy dose. This review summarizes and compares BH3 mimetics on the basis of specificity, mode of action and efficacy, as well as providing remarks on their therapeutical potential and routes of development in near future.
Keywords: ABT-737, anticancer, apoptosis, Bcl-2, BH3 mimetic, cancer, gossypol, small molecule inhibitor, obatoclax
Current Medicinal Chemistry
Title:Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Volume: 19 Issue: 12
Author(s): C. Bodur and H. Basaga
Affiliation:
Keywords: ABT-737, anticancer, apoptosis, Bcl-2, BH3 mimetic, cancer, gossypol, small molecule inhibitor, obatoclax
Abstract: Dose-limiting toxicity to healthy tissues is among the major hurdles in anticancer treatment along with intrinsic or acquired multi-drug resistance. Development of small molecule inhibitors (SMI) specific for antiapoptotic Bcl-2 proteins is a novel approach in a way that these antagonists are aimed to interfere with specific protein-protein interactions unlike conventional chemo-/radiotherapies. SMIs of antiapoptotic Bcl-2 proteins are assumed to compete with proapoptotic Bcl-2s to occupy BH3 docking grooves on the surfaces of antiapoptotic family members. Instead of directly initiating cell death, these inhibitors are intended to decrease apoptotic threshold in tumor cells that were already primed to death. In this regard, antiapoptotic Bcl-2 protein SMIs have the advantage of lower normal tissue toxicity relative to conventional anticancer therapies that interfere with general mechanisms including DNA synthesis, mitosis and tyrosine kinase activity. Besides, Bcl-2 antagonists were shown to potentiate efficacies of established drugs in several hematological malignancies and solid tumors which render them promising candidates for combination anticancer therapy. Utilizing these SMIs in such a way may prove to decrease the patient drug load by diminishing the required chemo-/radiotherapy dose. This review summarizes and compares BH3 mimetics on the basis of specificity, mode of action and efficacy, as well as providing remarks on their therapeutical potential and routes of development in near future.
Export Options
About this article
Cite this article as:
Bodur C. and Basaga H., Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy, Current Medicinal Chemistry 2012; 19 (12) . https://dx.doi.org/10.2174/092986712800099839
DOI https://dx.doi.org/10.2174/092986712800099839 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Application of Chitosan in Dental Specialities
Mini-Reviews in Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Sarcopenia in Ovarian Cancer Patients, Oncologic Outcomes Revealing the Importance of Clinical Nutrition: Review of Literature
Current Pharmaceutical Design Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design Complications of Paget Bone Disease: A Study of 69 Patients
Current Rheumatology Reviews The Impact of HAART on HPV-Related Cervical Disease
Current HIV Research Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa
Recent Patents on Nanomedicine Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E. Quinones-Mateu)]
Current HIV Research EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Current HIV Research Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Polyphenols Counteract Tumor Cell Chemoresistance Conferred by Multidrug Resistance Proteins
Anti-Cancer Agents in Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Chemical Constituents and Cytotoxicity of Euphorbia vajravelui
Letters in Organic Chemistry Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design